ST. LOUIS, March 03, 2026 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ: ADV) (“Advantage,” “Advantage Solutions,” the “Company,” “we,” or ...
Investors obviously didn't figure a significant bottom-line miss was in the cards for Figure Technology Solutions' (NASDAQ: FIGR) final quarter of 2025. That's a key reason they traded out of the next ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The national security-focused ...
Photos of City Pickle USA, part of the planned $1.1 billion North City development in north Fort Worth. Courtesy of Cooksey A solo developer has dreams for a $1.1 billion development in north Fort ...
I think about energy pretty simply. Right now works really well on some places and not well at all and others and even where it does work, it's understrength. Demand keeps rising, expectations keep ...
Hosted on MSN
Puzzle solutions for Sunday, Jan. 4, 2026
Note: Most subscribers have some, but not all, of the puzzles that correspond to the following set of solutions for their local newspaper. Start the day smarter. Get all the news you need in your ...
i've found a bug, where if two pages depend on a common CSS module, it gets unloaded when navigating from the first to the second page, thus breaking the styles. i enabled ssr: false on both pages and ...
Determining the least expensive path for a new subway line underneath a metropolis like New York City is a colossal planning challenge—involving thousands of potential routes through hundreds of city ...
A six-story building with offices, retail space and restaurants will anchor the corner of North University Drive at White Settlement Road (soon to be renamed Westside Drive) as part of the $1.7 ...
Atlassian Corp. announced its largest acquisition to date with its $1 billion cash-and-stock deal for developer productivity platform DX. The move comes as enterprises struggle to quantify returns on ...
Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results